CSL powers ahead with massive $1.9 billion profit
Biotechnology and blood plasma business CSL (ASX: CSL) powered ahead in the latest financial year recording net profit of more than 1.9 billion, up 17 per cent on the year before. The Parkville, Melbourne based company expects this year to show another profit growth of seven to 10 per cent as it executes its strategy…
Details










